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Abstract
Infiltration of leukocytes into premalignant tissue is a
common feature of many epithelial neoplasms and is
thought to contribute to cancer development. How-
ever, the molecular and cellular regulatory mecha-
nisms underlying activation of innate host responses
to enhanced neoplastic cell proliferation are largely
unknown. Considering the importance of the comple-
ment system in regulating inflammation during acute
pathologic tissue remodeling, we examined the func-
tional significance of complement component 3 (C3)
as a regulator of inflammatory cell infiltration and
activation during malignant progression by using a
transgenic mouse model of multistage epithelial carci-
nogenesis, e.g., HPV16 mice. Whereas abundant depo-
sition of C3 is a characteristic feature of premalignant
hyperplasias and dysplasias coincident with leuko-
cyte infiltration in neoplastic tissue, genetic elimina-
tion of C3 neither affects inflammatory cell recruitment
toward neoplastic skin nor impacts responding path-
ways downstream of inflammatory cell activation,
e.g., keratinocyte hyperproliferation or angiogenesis.
Taken together, these data suggest that complement-
independent pathways are critical for leukocyte
recruitment into neoplastic tissue and leukocyte-
mediated potentiation of tumorigenesis.
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Introduction
Tumors are composed of genetically altered cells, a variety
of responding host cells, including fibroblasts, vascular cells
(endothelial and mural cells), and a diverse array of inflam-
matory leukocytes embedded in a dynamic extracellular
matrix (ECM) microenvironment [1,2]. Accumulating clinical
and experimental data suggest that inflammatory leuko-
cytes provide essential regulatory roles for developing
tumors where their innate activities are conscripted by
neoplastic cells to make significant contributions to malig-
nant phenotypes [1–3]. The significance of inflammation
associated with cancer development is underscored by the
realization that tissues afflicted with chronic inflammatory
states, e.g., Crohn’s disease, ulcerative colitis, pancreatitis,
etc., exhibit increased risk for malignancy [4–7]. Moreover,
long-term users of anti-inflammatory drugs demonstrate re-
duced cancer risk [8–14]. Taken together, it seems reasonable
to suggest that therapeutic strategies targeting inflammatory
cell recruitment, activation, or response represent tractable
anticancer opportunities.
Complement activation is a central event during innate
immune defense after pathogenic tissue assault [15,16]. Three
different pathways of complement activation have been iden-
tified, namely, the classic, the alternative, and the lectin path-
ways [17–19]. Complement component C3 is a central protein
of the complement cascade, expression of which is essential
for activation of all three complement pathways [19]. Foreign
antigens and immune complexes activate the proteolytic com-
plement activation cascade, resulting in formation of lytic
membrane attack complexes (MAC) [17–19] and formation
and liberation of anaphylatoxins, e.g., C3a and C5a, potent
proinflammatory factors that induce recruitment and activation
of various inflammatory cells, in particular mast cells, eosino-
phils, and neutrophils [20–23]. Deposition of complement
component proteins is a common occurrence at sites of inflam-
mation [24–28]. Studies utilizing complement-depleted mice
and C3- or C5-deficient mice have identified crucial roles for
complement in mast cell recruitment and activation during
airway hyperresponsiveness [25,29,30], IgG–antigen com-
plex–mediated inflammation [31], intestinal ischemia/reperfu-
sion [32], delayed-type hypersensitivity [33], and subepidermal
blistering disease [34], thus underscoring the central role
complement plays in regulating disease pathogenesis.
Using a transgenic mouse model of multistage epithelial
carcinogenesis, e.g., HPV16 mice [35], we have investigated
the functional role of complement component 3 (C3) as a regu-
lator of inflammatory cell recruitment and premalignant pro-
gression. HPV16 mice express the early region genes of
human papillomavirus type 16 (HPV16) as transgenes under
control of the human keratin 14 promotor/enhancer [36]. By
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1 month of age, HPV16 mice develop epidermal hyper-
plasias with 100% penetrance that are characterized by a
terminally differentiating hyperproliferative epidermis atop a
dermal compartment rich in recruited activated mast cells
[37]. Hyperplastic lesions advance focally into angiogenic
dysplasias between 3 and 6 months of age and are distinct
from hyperplasias based on the prominent hyperproliferative
epidermis that fails to undergo terminal differentiation and a
dermis where intense mast cell and neutrophil infiltration
occurs proximal to dilated and enlarged angiogenic vascu-
lature [37–39]. By 1 year of age, 60% of HPV16 mice
develop malignant skin carcinomas, 50% of which are squa-
mous cell carcinomas (SCCs) that metastasize to regional
lymph nodes with anf30% frequency, andf10% of which
represent nonmetastatic microcystic adnexal carcinomas
(MACs) [38,40]. Mast cell deficiency in HPV16 mice signif-
icantly attenuates keratinocyte hyperproliferation and activa-
tion of angiogenesis, thus supporting the concept that
inflammation, and in particular activation of sentinel mast
cells and release of their factors, functionally contribute to
early neoplastic development in HPV16 mice [37].
In the present study, we report abundant deposition of C3
in neoplastic skin of HPV16 mice. To determine if C3 depo-
sition represented a functionally significant parameter of
mast cell recruitment, activation, or response, we generated
HPV16 mice harboring a homozygous null mutation in the
C3 gene, e.g., HPV16/C3/ mice [15,16]. Despite abun-
dant C3 deposition into the neoplastic microenviroment of
HPV16 mice, our data suggest that activation of the comple-
ment system does not functionally contribute to recruitment
of inflammatory cells, induction of keratinocyte hyperprolif-
eration, or activation of angiogenesis during epithelial neo-
plastic progression. Because abundant deposition of IgG
antibodies is an early event that is sustained throughout
neoplastic progression and coincides with inflammatory cell
infiltration, we propose an antibody-dependent but comple-
ment-independent pathway regulating mast cell recruitment
into neoplastic skin.
Materials and Methods
Transgenic Mice
Generation and characterization of HPV16 transgenic
mice and neoplastic staging based on keratin intermediate
filament expression has been described previously [35,36].
The generation of C3–deficient mice has been described
[15,16]. C3/mice were kindly provided by Dr. M. C. Carroll
(Harvard Medical School, Boston, MA). To generate HPV16
mice in the C3-deficient backgrounds, C3+/ mice were
individually backcrossed into the FVB/n strain to N19, where
they were then intercrossed with HPV16 mice to generate
a breeding colony of HPV16/C3/ and C3/ animals. All
mice were maintained within the University of California,
San Francisco, Laboratory for Animal Care facility according
to IACUC procedures. Genotyping of C3/mice was based
on a C3 ELISA where C3 levels in sera (or tissue) were
assayed using a polyclonal goat anti–mouse C3 antiserum
(1:500; ICN/Cappel, Irvine, CA). Because the C3 locus is
located near the MHC region, we confirmed H-2Kq expres-
sion and absence of H-2Db expression after backcrossing
into the FVB/n strain by FACS analysis using mouse
anti–mouse H-2Db and mouse anti–mouse H-2Kq mAbs
(BD Biosciences, San Diego, CA).
Immunofluorescence Detection of Antibody and C3
Depositions
Age-matched tissue samples from transgenic and control
animals were frozen directly in glycerol-based freezing
medium (OCT). For immunofluorescence (IF) detection of
antibody and C3 deposition, 10-mm OCT-embedded tissue
sections were cut with a Leica CM1900 cryostat. Sections
were air-dried, fixed in acetone for 5 minutes, and sub-
jected to IF staining as follows: sections were blocked
for 30 minutes in blocking buffer (5% goat serum/2.5%
BSA/PBS). For IF detection of antibodies, a 1:50 dilution of
rat anti–mouse CD16/CD32 mAb (BD Biosciences) was
added to the blocking buffer to prevent nonspecific antibody
binding. Fluorescein isothiocyanate (FITC)-conjugated goat
anti–mouse IgG (g-chain specific, 1:100; Sigma, St. Louis,
MO), and rat anti–mouse C3 (1:100; Caltag, Burlingame,
CA) were diluted in 0.5  blocking buffer and incubated with
tissue sections for 1 hour at room temperature, protected
from light. Sections were then extensively washed with PBS.
For IF detection of C3, sections were blocked for 5 minutes
in blocking buffer and incubated with FITC-conjugated goat
anti-rat (1:100, Jackson ImmunoResearch, West Grove, PA)
for 45 minutes at room temperature, protected from light.
Slides were then extensively washed with PBS before
mounting using Vectashield containing 4V,6 diamidino-2-
phenylindole (DAPI) (Vector, Burlingame, CA). All IF experi-
ments included negative controls for determination of back-
ground staining, which was negligible. Data shown are
representative of results obtained after examination of tis-
sues removed from a minimum of four mice per group.
Immuno- and Enzyme Histochemistry
Age-matched tissue samples from transgenic and control
animals were immersion-fixed in 10% neutral-buffered for-
malin followed by dehydration through graded alcohols and
xylene, and embedded in paraffin. Five-micrometer-thick
paraffin sections were cut using a Leica 2135 microtome.
Sections were deparaffinized and subjected to immunohis-
tochemical detection as previously described [41]. Primary
antibodies were diluted in blocking buffer (5% goat serum/
2.5% BSA/PBS) at 1:50 dilution for rat anti–mouse CD31
(BD Biosciences) and 1:500 for rat anti–mouse neutrophil-
specific primary antibody (Cedarlane Labs, Hornby, Ontario,
Canada). Sections were incubated with primary antibody for
2 to 4 hours at room temperature, followed by PBS washing,
brief (5 minutes) incubation in blocking buffer, and subse-
quent incubation with biotinylated secondary antibody (rabbit
anti–rat IgG 1:200, Vector) for 45 minutes at room temper-
ature. After PBS washing, Vectastain Elite ABC reagent
(Vector) was applied for 30 minutes. Sections were then
washed in PBS and endogenous peroxidase activity blocked
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by incubation in 30% H2O2 in methanol for 20 minutes.
Antibodies were visualized by treatment with Fast 3,3V-
diaminobenzodine (Sigma), dehydrated in graded alcohols
(70%, 95%, and 100% ethanol), and mounted in Cytoseal 60
(Richard-Allan Scientific, Kalamazoo, MI).
Chloroacetate esterase (CAE) histochemistry was per-
formed to visualize serine esterase activity in mast cells as
previously described [37]. Briefly, 1 mg of naphthol AS-D
chloroacetate (Sigma) was dissolved in 20 ml of N,N-dimethyl
formamide (DMF) and 1 ml buffer (8% DMF, 20% ethylene
glycol monoethylether in 80 mM Tris-maleate, pH 7.5).
Subsequently, 1 mg Fast Blue BB salt (Fluka, Buchs,
Switzerland) was added, the solution filtered using a
0.45-mm filter and applied to deparaffinized paraffin sections
for 5 minutes. Sections were rinsed in PBS, dehydrated, and
mounted in glycerol. Quantitative analysis of mast cells and
neutrophils was performed by counting cells in five high-
power fields (40 ) per age/staged tissue section from five
mice per neoplastic stage. Data presented reflect the aver-
age total cell count per field from the ventral ear leaflet.
Statistical analysis was performed using GraphPad InStat
version 3.0a for Macintosh (GraphPad Software, San Diego,
CA). The specific tests that were used were the Mann-
Whitney (unpaired, nonparametric two-tailed) test and the
Fishers (unpaired) t test. P < .05 was considered statistically
significant. All immunolocalization experiments were repeat-
ed on multiple tissue sections and included negative controls
for determination of background staining, which was negli-
gible. Data shown are representative of results obtained af-
ter examination of tissues removed from a minimum of four
different mice per distinctive stage of neoplastic progression.
Determination of Keratinocyte Proliferation Index
To detect bromodeoxyuridine (BrdU)-positive keratino-
cytes in neoplastic and control tissues, animals received
intraperitoneal injections of BrdU (Roche, Indianapolis, IN)
dissolved in PBS at 50 mg/g total body weight 90 minutes
before sacrifice and preparation of tissue samples. Five-
micrometer-thick paraffin sections were deparaffinized in
xylenes, rehydrated in graded ethanol, boiled in Citra antigen
retrieval solution (BioGenex, San Ramon, CA), washed in
PBS, and blocked in blocking buffer and BrdU-positive cells
were detected essentially as described by the manufactur-
er’s recommendations using the BrdU Labeling Kit II
(Roche), developed by Vector Red Alkaline Phosphatase
Kit (Vector), counterstained with eosin, dehydrated through
graded ethanol and xylenes, and mounted in Cytoseal 60
(Richard-Allan Scientific). Images used for quantification
were captured at high magnification (40 ) on a Leica DM-
RXAmicroscope attached to a Leica digital camera operated
by OpenLab software (Improvision, Lexington, MA). The
proliferative index was quantified from five high-power
(40 ) images per neoplastically staged tissue and included
four mice per category as the percentage of BrdU-positive
nuclei over the total number of keratinocytes. Statistical
analysis was performed using GraphPad InStat version
3.0a for Macintosh (GraphPad Software). The specific tests
that were used were the Mann-Whitney (unpaired, non-
parametric two-tailed) test, and the Fishers (unpaired) t test.
P < .05 was considered statistically significant.
Flow Cytometry
The magnitude of inflammatory infiltrate in neoplastic
tissues was analyzed by flow cytometry. Ear skin biopsies
from ()LM, HPV16mice, and HPV16/C3/mice at specific
time points were manually minced using a scalpel, followed
by a 13-minute enzymatic digestion with 2.5 mg/ml collage-
nase Type II (Worthington, Lakewood, NJ), 2.5 mg/ml colla-
genase Type IV (Gibco, Carlsbad, CA), and 0.5 mg/ml
DNase (Sigma) in PBS containing 1% BSA (Sigma) (PBS/
BSA) at 37jC under continuous stirring conditions. The
digest was quenched by adding Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco) containing 10% FBS (Gibco) and
was filtered through a 70-mm nylon filter (Falcon). Single-cell
suspensions were treated with PharM Lyse ammonium
chloride lysing reagent (BD Biosciences) for 10 minutes to
remove erythrocytes. Cells were washed with DMEM con-
taining 10% FBS, followed by a wash with PBS/BSA. Cells
were incubated for 10 minutes at 4jC with rat anti–mouse
CD16/CD32 mAb (BD Biosciences) at a 1:50 dilution in PBS/
BSA to prevent nonspecific antibody binding. Subsequently,
cells were washed and incubated for 20 minutes with 50 ml
of 1:100 dilution of APC-conjugated anti–mouse CD45
(eBioscience, San Diego, CA). Cells were washed twice
with PBS/BSA and 7-AAD (BD Biosciences) was added at
a dilution of 1:10 to discriminate between viable and dead
cells. Data acquisition and analysis were performed on a
FACSCalibur using CellQuestPro software (BD Bioscien-
ces). Statistical analysis was performed using GraphPad
InStat version 3.0a for Macintosh (GraphPad Software,
San Diego, CA). The specific tests that were used were the
Mann-Whitney (unpaired, non parametric two-tailed) test,
and the Fishers (unpaired) t test. P < 0.05 was considered
statistically significant.
Results
Neoplastic Progression in HPV16 Mice Is Characterized by
C3 Deposition
Early neoplastic progression in HPV16 mice is character-
ized by a dramatic influx of cells of the innate immune
system, in particular mast cells and neutrophils [37,38]. To
investigate whether the observed accumulation of inflamma-
tory cells in the neoplastic microenvironment was accompa-
nied by activation of the complement system, C3 deposition
was examined by IF microscopy on tissue sections and
ELISA with tissue lysates (Figure 1). Whereas only minimal
detection of C3 was observed in nontransgenic skin, abun-
dant dermal deposits of C3 were prominent in hyperplastic
and dysplastic skin of HPV16 mice (Figure 1). Using a C3
ELISA, we found a statistically significant increase in C3
levels in hyperplastic skin lysates from 1-month-old HPV16
mice compared with nontransgenic controls (P < .05, Fishers
(unpaired) t test; data not shown). As expected, C3 staining
and immunoreactivity (based on ELISA) was not observed
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in C3/ mice (data not shown). These data suggest that
neoplastic progression in HPV16 mice is characterized by
early activation of the complement system and C3 accumu-
lation coincident with initial development of hyperplasias.
Moreover, C3 accumulation becomes more pronounced as
neoplastic progression to dysplasia ensues, suggesting that
activation of complement represents an early parameter of
premalignant progression in HPV16 mice.
Infiltration of Inflammatory Cells during Neoplastic
Progression Is Not Reduced in the Absence of C3
Previous studies using HPV16 mice have revealed an
important role for bone-marrow-derived inflammatory cells
during skin carcinogenesis [37–39,42]. Given the critical role
of the complement system in recruitment and activation
of inflammatory cells during pathologic tissue remodeling
[25,29,30,32–34,43,44], in combination with the observa-
tion that deposition of C3 is already detectable in hyperplas-
tic skin lesions of HPV16 mice (Figure 1), we hypothesized
that complement mediates recruitment of inflammatory cells
toward neoplastic skin. To test this hypothesis, we took a
genetic approach and generated HPV16/C3/ mice [15,16]
and examined several key characteristics of neoplastic pro-
gression in the absence and presence of C3.
To determine whether absence of C3 in HPV16/C3/
mice altered characteristic inflammatory cell recruitment into
early neoplastic lesions, we first profiled infiltration of leu-
kocytes by quantitative detection of CD45 (leukocyte com-
mon antigen)-positive cells in age-matched neoplastic tissue
from HPV16/C3/ and HPV16 mice by flow cytometry
(Figure 2A). This analysis revealed that the magnitude of
the inflammatory infiltrate is most striking in early dysplasias
(4 months of age), where f35% of all cells are CD45+
inflammatory cells (Figure 2A). Surprisingly, the absence of
C3 in HPV16/C3/ mice did not result in any quantitative
changes in this profile of infiltrating CD45-positive leukocytes
(Figure 2A, Mann-Whitney test).
To investigate the possibility that C3 deficiency resulted
in a shift in immune cell profile, we quantitatively assessed
the two major immune cell populations infiltrating HPV16
neoplastic skin, namely, mast cells and neutrophils [37,38].
We used CAE histochemistry on paraffin-embedded age-
matched tissue sections to detect serine esterase activity
in mast cells in situ. As described previously [37], normal
nontransgenic skin contains fewmast cells distributed broad-
ly throughout the dermis (Figure 2B). Mast cell numbers
increase beginning in hyperplasias (1 month of age) and
further increase with the onset of intense angiogenesis in
dysplastic lesions (Figure 2B). Quantitative analysis of
the number of mast cells in situ revealed that the number
of infiltrating mast cells in skin from age-matched HPV16/
C3/ mice was indistinguishable from that detected in age-
matched HPV16 controls (Figure 2B, Mann-Whitney test),
suggesting that C3 is not required for recruitment of mast
cells into premalignant skin lesions.
To assess if C3 instead regulated neutrophil recruitment,
we quantitatively compared neutrophils in age-matched
HPV16 and HPV16/C3/ mice and found no significant
differences (Figure 2C, Mann-Whitney test), suggesting that
C3 is not involved in the recruitment of either mast cell or
neutrophils into premalignant skin. Thus, although deposition
of C3 in neoplastic skin coincides with infiltration of inflam-
matory cells, C3 does not mediate the recruitment of inflam-
matory cells into the neoplastic microenvironment.
Activation of Keratinocyte Hyperproliferation and Angiogen-
esis during Neoplastic Progression Are not Regulated by C3
Although C3 does not appear to be essential for recruit-
ment of inflammatory cells toward neoplastic lesions, we
reasoned that C3 could instead be critical for activation of
inflammatory cells in the neoplastic microenvironment. Mast
cells secrete a variety of mitogenic factors affecting a wide
range of cell types, including keratinocytes and endothelial
cells [37,42,45–49]. Using mast-cell-deficient/HPV16 mice,
we previously reported that mast cells contribute to neo-
plastic progression by potentiating keratinocyte hyperprolif-
eration and activating angiogenesis [37], in part by release of
matrix metalloproteinase-9 (MMP9) [38,42]. Together, these
data suggest that activation of mast cells is an important
contributing event to tumorigenesis in HPV16 mice. To
assess whether C3 was involved in mast cell activation we
compared keratinocyte proliferation indices and activation
of angiogenic vasculature as readouts for mast cell activation
in HPV16 and HPV16/C3/ mice.
Figure 1. Deposition of C3 in the neoplastic microenvironment. Immunofluorescence for C3 (FITC signal) on 10-m OCT-embedded frozen tissue sections in
(A) negative littermate (LM) ear skin, (B) hyperplastic (1 month of age), (C) early dysplastic (4 months of age), and (D) late dysplastic (6 months of age) ear tissue
from HPV16 mice. Dashed line indicates epidermal–dermal interface. The epidermis (e), dermis (d), and cartilage (c) are indicated. Scale bar: 50 m (A–D).
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Hyperproliferation is an intrinsic property of neoplastic
cells. Accordingly, we previously reported that keratinocyte
hyperproliferation incrementally increases during neoplastic
progression in HPV16 mice and, in part, characterizes
progression between premalignant stages [35,36]. Keratino-
cyte proliferative indices were determined in age-matched
skin from HPV16 and HPV16/C3/ mice and were found to
be similar at each neoplastic stage examined (Figure 3A,
Mann-Whitney test), suggesting that C3 is not involved in
regulating epithelial hyperproliferation downstream of mast
cell activation.
The vascular architecture changes in a characteristic
manner during neoplastic progression in HPV16 mice
[37,38] and can be monitored by immunodection of the
endothelial cell-specific marker CD31. Normal nontrans-
genic mouse skin contains infrequent capillaries located
deep within the dermis (Figure 3B). Neoplastic progression
involves an early increase in capillary density first evident
subjacent to hyperplastic epithelium, whereas dysplastic
lesions contain dilated and enlarged capillaries that are
increased in number indicative of an angiogenic switch from
vascular quiescence to modest neovascularization in early
low-grade lesions (hyperplasias) to a striking upregulation of
angiogenesis in high-grade lesions (dysplasias) (Figure 3B).
Comparison of vascular architecture, density, and patterning
during premalignant progression in HPV16 andHPV16/C3/
mice failed to reveal any differences (Figure 3B), suggesting
that C3 does not contribute to inflammatory cell-mediated
activation of angiogenic vasculature.
IgG Deposition Suggests Antibody-Dependent, but Comple-
ment-Independent Regulation of Neoplasia-Associated
Inflammation
Despite the fact that complement activation plays a
prominent role in regulating many immunologic injuries
[25,29–34,50] and significant deposition of C3 is observed
in dermal compartments of neoplastic skin, the absence of
C3 did not functionally alter leukocyte recruitment or activa-
tion during premalignant progression in HPV16 mice. Inflam-
matory cells can, however, be recruited and activated
directly by antibodies through cross-linking of antibody sur-
face receptors, e.g., Fcg and/or Fcq receptors [51,52]. To
study whether the humoral immune response is involved in
regulating inflammation in HPV16 mice, the spatial and
temporal deposition patterns of IgG antibodies in neoplastic
skin were analyzed by IF (Figure 4). In negative littermate
nontransgenic skin, low IgG immunoreactivity was detect-
able in the dermis (Figure 4). In HPV16 hyperplastic skin
(1 month of age), extensive regions of IgG antibodies
were visualized throughout the dermis that was further
expanded and intensified in dysplastic lesions (4 to 6
months of age) (Figure 4). HPV16/C3/ mice displayed
Figure 2. Infiltration of inflammatory cells during neoplastic progression is
not reduced in the absence of C3. (A) Single-cell suspensions derived from
negative littermate ear tissue (LM) and hyperplastic (1 month of age), early
dysplastic (4 months of age), and late dysplastic (6 months of age) ear tissue
from HPV16 mice and HPV16/C3/ mice were analyzed by flow cytometry
to determine the percentage of CD45+ cells as a percentage of total viable
cells (n = 3). Results are shown as mean percentages ± SEM. No statistically
significant differences were observed between age-matched neoplastic
tissues of HPV16 and HPV16/C3/ mice (Mann-Whitney unpaired t test).
(B) Quantitative analysis of mast cells at distinct stages of neoplastic
progression in ear tissue from HPV16, HPV16/C3/ mice, and negative
littermates (LM). Mast cells were visualized by CAE histochemistry on 5-m
paraffin-embedded tissue sections. Values represent number of mast cells,
averaged from five high-power fields per mouse and five mice per category.
Error bars represent SEM. No statistically significant differences were
observed between age-matched neoplastic tissues between HPV16 and
HPV16/C3/ mice (Mann-Whitney unpaired t test). (C) Quantitative analysis
of neutrophils at distinct stages of neoplastic progression in ear tissue from
negative littermate ()LM, HPV16, and HPV16/C3/ mice. Neutrophils were
visualized by immunohistochemistry on 5-m paraffin-embedded tissue
sections. Values represent number of neutrophils, averaged from five high-
power fields per mouse and five mice per category. Error bars represent
SEM. No statistically significant differences were observed between age-
matched neoplastic tissues between HPV16 and HPV16/C3/ mice (Mann-
Whitney unpaired t test).
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similar IgG deposition patterns during neoplastic progression
(Figure 4), suggesting that an antibody-mediated immune
response independent of complement activation and C3
deposition might therefore be involved in mediating recruit-
ment of inflammatory cells during malignant progression in
HPV16 mice.
Figure 3. Activation of keratinocyte hyperproliferation and angiogenesis during neoplastic progression is not affected in the absence of C3. (A) Quantitative
analysis of the percentage of BrdU-positive keratinocytes (keratinocyte proliferative index) at distinct stages of neoplastic progression in ear tissue of HPV16 and
HPV16/C3/ mice at 1, 4, and 6 months of age. BrdU+ cells were visualized by immunohistochemical detection on 5-m paraffin-embedded tissue sections.
Values represent keratinocyte proliferative indices, averaged from five high-power fields per mouse and four to eight mice per category. Error bars represent SEM.
No statistically significant differences were observed between age-matched neoplastic tissues between HPV16 and HPV16/C3/ mice (Mann-Whitney unpaired
t test). (B) Immunolocalization of CD31/PECAM-1 (black staining) in 5-m paraffin-embedded sections of age-matched neoplastic ear tissue of HPV16 and HPV16/
C3/mice and in ear tissue of negative littermate (LM) mice reveals no difference between dilated and enlarged capillaries comparing HPV16 and HPV16/C3/
mice at all ages tested. Dashed line indicates epidermal–dermal interface. Arrowheads indicate representative blood vessels. The epidermal (e), dermal (d), and
cartilage (c) regions of the tissues are indicated. Scale bar: 50 m.
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Discussion
In the present study we examined the functional significance
of C3 deposition and complement activation in a mouse
model of epithelial carcinogenesis characterized, in part, by
prominent inflammatory cell infiltrates in premalignant
lesions. Results from this study suggest that C3 is neither
required for the dramatic accumulation of inflammatory cells
in premalignant skin nor influences the contributory role of
inflammatory cells to squamous carcinogenesis, e.g., kera-
tinocyte hyperproliferation or activation of angiogenic vascu-
lature. These data stand in contrast to studies showing a
crucial role for complement in recruitment and activation of
inflammatory cells in other states of pathologic remodeling,
e.g., airway hyperresponsiveness [25,29,30], IgG–antigen
complex–mediated inflammation [31], intestinal ischemia/
reperfusion [32,50], delayed-type hypersensitivity [33], and
subepidermal blistering disease [34].
The experimental model of IgG-mediated subepidermal
blistering disease [34,43,44] has many characteristics in
common with the HPV16mouse model of de novomultistage
skin carcinogenesis, namely, deposition of IgG and comple-
ment at the dermal–epidermal junction and recruitment of
Figure 4. IgG deposition in the neoplastic microenvironment of HPV16 mice. Direct immunofluorescence on 10-m OCT-embedded frozen tissue sections detects
IgG antibodies (FITC signal) in negative littermate (LM) ear skin, hyperplastic (1 month of age), early dysplastic (4 months of age), and late dysplastic (6 months
of age) ear tissue from HPV16 and HPV16/C3/ mice. Dashed line indicates epidermal –dermal interface. The epidermis (e), dermis (d), and cartilage (c) are
indicated. Scale bar: 50 m.
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mast cells and neutrophils [34]. Moreover, subepidermal
blister formation is mediated by mast cell activation; mast-
cell-deficient mice are resistant to experimental subepider-
mal blistering disease [44]. Likewise, we have previously
reported that mast-cell-deficient/HPV16 mice display atten-
uated characteristics of neoplastic progression [37]. How-
ever, whereas subepidermal blistering disease depends on
complement activation, as complement component C5–de-
ficient mice failed to develop cutaneous blisters [34], no
functional significance of the complement system was ob-
served in our study. To our knowledge, this is the first report in
which the role of the complement system in a model of de
novo neoplastic progression has been investigated.
Why is neoplastic progression and its accompanied in-
flammation not altered by deficient complement activation?
The major difference between inflammation associated with
malignant progression and that associated with other states
of pathologic remodeling, e.g., subepidermal blistering dis-
ease, airway hyperresponsiveness, intestinal ischemia/
reperfustion, and delayed hypersensitivity, is the duration
of inflammatory response. Inflammation during neoplastic
progression is not abated because the ‘‘wound does not
heal’’ [2]; thus, inflammatory cells fail to egress out of
neoplastic tissue, therefore representing a chronic disease
state. Moreover, antigens that are likely important for acti-
vation of the adaptive immune system similarly are present
chronically and likely induce chronic B-cell responses, result-
ing in significant antibody deposition into neoplastic tissue.
If complement is not required for recruitment of inflam-
matory cells toward premalignant lesions, what other com-
plement-independent recruitment pathways might be
involved? Inflammatory cells can be recruited and activated
through a complement-independent, antibody-dependent
pathway. Antibodies can interact directly with inflammatory
cells through antibody binding surface receptors, e.g., Fcg
and/or Fcq receptors [51,52]. Fc receptors are multimeric
cell-surface receptors that bind the Fc portion of antibodies
and are expressed by many hematopoietic cells [53]. Anti-
body-mediated cross-linking of Fc receptors results in re-
cruitment and activation of inflammatory cells. For example,
in IgE-associated hypersensitivity reactions and allergic dis-
orders, mast cell activation is initiated by cross-linking of IgE
bound to the high-affinity FcqRI receptors, resulting in secre-
tion of products that can have effector, immunoregulatory, or
autocrine effects [51]. It has become clear that in addition
to IgE-dependent recruitment mechanisms, IgG-dependent
mechanisms can regulate recruitment and activation of mast
cells through Fcg receptors [52]. In vitro incubation of human
mast cells through Fcg RI with IgG1 antibodies resulted in
degranulation, increased production of arachidonic acid
metabolites, and tumor necrosis factor-a release [52]. Fcg
receptor–deficient mice are resistant to development of
experimental immune hemolytic anemia and immune throm-
bocytopenia [54]. Likewise, Fcg receptor expression on mast
cells has been reported to promote the course of experimen-
tal allergic encephalomyelitis (EAE) [55]. In addition, anti-
body-mediated experimental cutaneous Arthus reaction
requires expression of Fcg receptors on inflammatory cells
and develops normally in complement-deficient mice [56,57].
Thus, activation of cell-surface Fcg receptors can result in
activation of an inflammatory response independent of com-
plement activation. We observed early and abundant
deposition of IgG antibodies in premalignant skin lesions
(Figure 4) and the spatial and temporal deposition profile
of IgG antibodies coincided with the inflammatory infiltrate;
thus we are currently investigating whether antibodies local-
ized in the neoplastic microenvironment trigger complement-
independent recruitment and activation of mast cells.
Because inflammatory cells, and in particular mast cells,
are important contributors to the early stages of carcinogen-
esis in HPV16 mice as well as during human epithelial
carcinogenesis, a detailed understanding of the molecules
and mechanisms involved in activating the dramatic recruit-
ment will eventually facilitate the rational design of novel
therapies against human cancer.
Acknowledgements
We thank M. C. Carroll for kindly providing C3/ mice. We
also thank Alexandra Eichten for critically reading the
manuscript, members of the Coussens laboratory for
insightful discussion, Evelyn Galenski for administrative
assistance, and Eva Soliven, William Hyun, and Sarah
Elmes for technical assistance. K. E. dV. is supported by a
fellowship from the Dutch Cancer Society. LMC is supported
by grants from the National Institutes of Health, National
Cancer Institute, and Department of Defense.
References
[1] Bissell MJ and Radisky D (2001). Putting tumors in context. Nat Rev
Cancer 1, 46–54.
[2] Coussens LM and Werb Z (2002). Inflammation and cancer. Nature
420, 860–867.
[3] Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell
100, 57–70.
[4] Weitzman SA and Gordon LI (1990). Inflammation and cancer: role of
phagocyte-generated oxidants in carcinogenesis. Blood 76, 655–663.
[5] Ness RB and Cottreau C (1999). Possible role of ovarian epithelial
inflammation in ovarian cancer. J Natl Cancer Inst 91, 1459–1467.
[6] Shacter E and Weitzman SA (2002). Chronic inflammation and cancer.
Oncology 16, 217–226.
[7] Ernst PB and Gold BD (2000). The disease spectrum of Helicobacter
pylori: the immunopathogenesis of gastroduodenal ulcer and gastric
cancer. Annu Rev Microbiol 54, 615–640.
[8] Williams CS, Mann M, and DuBois RN (1999). The role of cyclooxy-
genases in inflammation, cancer, and development. Oncogene 18,
7908–7916.
[9] Garcia-Rodriguez LA and Huerta-Alvarez C (2001). Reduced risk of
colorectal cancer among long-term users of aspirin and nonaspirin non-
steroidal antiinflammatory drugs. Epidemiology 12, 88–93.
[10] Meier CR, Schmitz S, and Jick H (2002). Association between acet-
aminophen or nonsteroidal antiinflammatory drugs and risk of develop-
ing ovarian, breast, or colon cancer. Pharmacotherapy 22, 303–309.
[11] Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, and Hanley JA
(2000). Nested case–control study of the effects of non-steroidal anti-
inflammatory drugs on breast cancer risk and stage. Br J Cancer 83,
112–120.
[12] Cotterchio M, Kreiger N, Sloan M, and Steingart A (2001). Nonsteroidal
anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol
Biomarkers Prev 10, 1213–1217.
[13] Akre K, Ekstrom AM, Signorello LB, Hansson LE, and Nyren O (2001).
Aspirin and risk for gastric cancer: a population-based case–control
study in Sweden. Br J Cancer 84, 965–968.
[14] Gonzalez-Perez A, Rodriguez L, and Lopez-Ridaura R (2003). Effects
Complement and Neoplastic Progression de Visser et al. 775
Neoplasia . Vol. 6, No. 6, 2004
of non-steroidal anti-inflammatory drugs on cancer sites other than the
colon and rectum: a meta-analysis. BMC Cancer 3, 1–12.
[15] Prodeus AP, Zhou X, Maurer M, Galli SJ, and Carroll MC (1997).
Impaired mast cell-dependent natural immunity in complement C3-
deficient mice. Nature 390, 172–175.
[16] Wessels MR, Butko P, Ma M, Warren HB, Lage AL, and Carroll MC
(1995). Studies of group B streptococcal infection in mice deficient in
complement component C3 or C4 demonstrate an essential role for
complement in both innate and acquired immunity. Proc Natl Acad
Sci USA 92, 11490–11494.
[17] Walport MJ (2001). Complement. First of two parts. N Engl J Med 344,
1058–1066.
[18] Walport MJ (2001). Complement. Second of two parts. N Engl J Med
344, 1140–1144.
[19] Sahu A and Lambris JD (2001). Structure and biology of complement
protein C3, a connecting link between innate and acquired immunity.
Immunol Rev 180, 35–48.
[20] Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S,
Haase I, Lippert U, and Zuberbier T (1997). C3a and C5a stimulate
chemotaxis of human mast cells. Blood 89, 2863–2870.
[21] Johnson AR, Hugli TE, and Muller-Eberhard HJ (1975). Release of
histamine from rat mast cells by the complement peptides C3a and
C5a. Immunology 28, 1067.
[22] DiScipio RG, Daffern PJ, Jagels MA, Broide DH, and Sriramarao P
(1999). A comparison of C3a and C5a-mediated stable adhesion of
rolling eosinophils in postcapillary venules and transendothelial migra-
tion in vitro and in vivo. J Immunol 162, 1127–1136.
[23] Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe
DD, Siegbahn A, and Murphy PM (1996). C3a and C5a are chemo-
taxins for human mast cells and act through distinct receptors via a
pertussis toxin-sensitive signal transduction pathway. J Immunol 157,
1693–1698.
[24] Lapiere JC, Guitart J, Ettlin DA, Chen DM, Amagai M, and Chan LS
(1998). Preferential activation of the complement system in the lower
epidermis of patients with pemphigus vulgaris. Br J Dermatol 139,
851–854.
[25] Walters DM, Breysse PN, Schofield B, and Wills-Karp M (2002). Com-
plement factor 3 mediates particulate matter-induced airway hyperres-
ponsiveness. Am J Respir Cell Mol Biol 27, 413–418.
[26] Berstad AE, Brandtzaeg P, Stave R, and Halstensen TS (1997).
Epithelium related deposition of activated complement in Helicobacter
pylori associated gastritis. Gut 40, 196–203.
[27] Sugita Y, Morita E, Kawamoto H, Horiuchi K, Yamada S, Koro O, and
Yamamoto S (2000). Correlation between deposition of immuno-
components and infiltration pattern of polymorphonuclear leukocytes
in the lesions of chronic urticaria. J Dermatol 27, 157–162.
[28] Halstensen TS, Mollnes TE, Garred P, Fausa O, and Brandtzaeg P
(1990). Epithelial deposition of immunoglobulin G1 and activated com-
plement (C3b and terminal complement complex) in ulcerative colitis.
Gastroenterology 98, 1264–1271.
[29] Drouin SM, Corry DB, Kildsgaard J, and Wetsel RA (2001). Cutting
edge: the absence of C3 demonstrates a role for complement in Th2
effector functions in a murine model of pulmonary allergy. J Immunol
167, 4141–4145.
[30] Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U,
Ames RS, Sohns B, Flemme N, Meyer zu Vilsendorf A, Grove M, et al.
(2000). Cutting edge: guinea pigs with a natural C3a-receptor defect
exhibit decreased bronchoconstriction in allergic airway disease: evi-
dence for an involvement of the C3a anaphylatoxin in the pathogenesis
of asthma. J Immunol 165, 5401–5405.
[31] Zhang Y, Ramos BF, and Jakschik BA (1995). The role of mast cells
and their mediators in IgG–antigen complex–mediated inflammation.
Am J Ther 2, 761–767.
[32] Andoh A, Fujiyama Y, Araki Y, Kimura T, Tsujikawa T, and Bamba T
(2001). Role of complement activation and mast cell degranulation in
the pathogenesis of rapid intestinal ischemia/reperfusion injury in rats.
Digestion 63 (Suppl 1), 103–107.
[33] Szczepanik M, Akahira-Azuma M, Bryniarski K, Tsuji RF, Kawikova I,
Ptak W, Kiener C, Campos RA, and Askenase PW (2003). B-1 B cells
mediate required early T cell recruitment to elicit protein-induced
delayed-type hypersensitivity. J Immunol 171, 6225–6235.
[34] Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, and Diaz LA
(1995). The role of complement in experimental bullous pemphigoid.
J Clin Invest 95, 1539–1544.
[35] Coussens LM, Hanahan D, and Arbeit JM (1996). Genetic predisposi-
tion and parameters of malignant progression in K14-HPV16 transgenic
mice. Am J Pathol 149, 1899–1917.
[36] Arbeit JM, Munger K, Howley PM, and Hanahan D (1994). Progressive
squamous epithelial neoplasia in K14-human papillomavirus type 16
transgenic mice. J Virol 68, 4358–4368.
[37] Coussens LM,RaymondWW,BergersG, Laig-WebsterM, Behrendtsen
O, Werb Z, Caughey GH, and Hanahan D (1999). Inflammatory mast
cells up-regulate angiogenesis during squamous epithelial carcinogen-
esis. Genes Dev 13, 1382–1397.
[38] van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, and
Coussens LM (2002). Epithelial carcinogenesis: dynamic interplay be-
tween neoplastic cells and their microenvironment. Differentiation 70,
501–623.
[39] Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, and
Hanahan D (2003). Immune enhancement of skin carcinogenesis by
CD4+ T cells. J Exp Med 197, 1017–1028.
[40] Rhee JS, Diaz R, Korets L, Hodgson JG, and Coussens LM
(2004). TIMP-1 alters susceptibility to carcinogenesis. Cancer Res
64, 952–961.
[41] Coussens LM, Hanahan D, and Arbeit J (1996). Genetic predisposition
and parameters of malignant progression in K14-HPV16 transgenic
mice. Am J Pathol 149, 1899–1917.
[42] Coussens LM, Tinkle CL, Hanahan D, and Werb Z (2000). MMP-9
supplied by bone marrow-derived cells contributes to skin carcinogen-
esis. Cell 103, 481–490.
[43] Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, and Giudice
GJ (1993). A passive transfer model of the organ-specific auto-
immune disease, bullous pemphigoid, using antibodies generated
against the hemidesmosomal antigen, BP180. J Clin Invest 92,
2480–2488.
[44] Chen R, Fairley JA, ZhaoML, Giudice GJ, Zillikens D, Diaz LA, and Liu Z
(2002). Macrophages, but not T and B lymphocytes, are critical for
subepidermal blister formation in experimental bullous pemphigoid:
macrophage-mediated neutrophil infiltration depends on mast cell acti-
vation. J Immunol 169, 3987–3992.
[45] Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP,
Dvorak HF, and Galli SJ (1998). Mast cells can secrete vascular
permeability factor/vascular endothelial cell growth factor and exhibit
enhanced release after immunoglobulin E-dependent upregulation of
fc epsilon receptor I expression. J Exp Med 188, 1135–1145.
[46] Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H,
Welker P, Lippert U, Henz BM, and Moller A (1998). Synthesis, storage,
and release of vascular endothelial growth factor/vascular permeability
factor (VEGF/VPF) by human mast cells: implications for the biological
significance of VEGF206. Mol Biol Cell 9, 875–884.
[47] Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, and Caughey
GH (1999). Mast cell expression of gelatinases A and B is regulated by
kit ligand and TGF-beta. J Immunol 162, 5528–5535.
[48] Stevens RL, Friend DS, McNeil HP, Schiller V, Ghildyal N, and Austen
KF (1994). Strain-specific and tissue-specific expression of mouse
mast cell secretory granule proteases. Proc Natl Acad Sci USA 91,
128–132.
[49] Reynolds DS, Stevens RL, Lane WS, Carr MH, Austen KF, and Serafin
WE (1990). Different mouse mast cell populations express various
combinations of at least six distinct mast cell serine proteases. Proc
Natl Acad Sci USA 87, 3230–3234.
[50] Kimura T, Andoh A, Fujiyama Y, Saotome T, and Bamba T (1998).
A blockade of complement activation prevents rapid intestinal ischae-
mia– reperfusion injury by modulating mucosal mast cell degranulation
in rats. Clin Exp Immunol 111, 484–490.
[51] Kawakami T and Galli SJ (2002). Regulation of mast-cell and basophil
function and survival by IgE. Nat Rev Immunol 2, 773–786.
[52] Woolhiser MR, Okayama Y, Gilfillan AM, and Metcalfe DD (2001). IgG-
dependent activation of human mast cells following up-regulation of
FcgammaRI by IFN-gamma. Eur J Immunol 31, 3298–3307.
[53] Janeway CA, Travers P, Walport M, and Shlomchik MJ (2001). Immu-
nobiology: The Immune System in Health and Disease, 5th ed. Garland
Publishing, New York.
[54] Clynes R and Ravetch JV (1995). Cytotoxic antibodies trigger inflam-
mation through Fc receptors. Immunity 3, 21–26.
[55] Robbie-Ryan M, Tanzola MB, Secor VH, and Brown MA (2003). Cutting
edge: both activating and inhibitory Fc receptors expressed on mast
cells regulate experimental allergic encephalomyelitis disease severity.
J Immunol 170, 1630–1634.
[56] Sylvestre DL and Ravetch JV (1996). A dominant role for mast cell Fc
receptors in the Arthus reaction. Immunity 5, 387–390.
[57] Sylvestre DL and Ravetch JV (1994). Fc receptors initiate the Arthus
reaction: redefining the inflammatory cascade. Science 265, 1095–
1098.
776 Complement and Neoplastic Progression de Visser et al.
Neoplasia . Vol. 6, No. 6, 2004
